Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer is a paper indexed in PICO Portal from OpenAlex.
How many citations does Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer have?
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer has 26 citations in the OpenAlex counts PICO Portal stores.
When was Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer published?
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer has 2016 year in the PICO Portal index.
What is the open-access status of Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer?
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer has diamond oa status in the PICO Portal index.
What is the DOI of Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer?
The DOI for Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer is on the source record.
What is the PMID of Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer?
The PMID for Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer is on the source record.
What is the OpenAlex record for Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer?
The OpenAlex for Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer is on the source record.